GC
NTLA icon

Guggenheim Capital’s Intellia Therapeutics NTLA Stock Holding History

Guggenheim Capital’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.01M Buy
59,739
+4,622
+8% +$64.7K 0.01% 1018
2026
Q1 		$707K Sell
55,117
-144
-0.3% -$1.83K 0.01% 1100
2025
Q4 		$497K Buy
55,261
+12,160
+28% +$167K ﹤0.01% 1281
2025
Q3 		$744K Sell
43,101
-6,820
-14% -$84K 0.01% 1028
2025
Q2 		$468K Sell
49,921
-5,668
-10% -$46.5K ﹤0.01% 1219
2025
Q1 		$395K Sell
55,589
-4,000
-7% -$40.4K ﹤0.01% 1314
2024
Q4 		$695K Sell
59,589
-7,358
-11% -$115K 0.01% 1109
2024
Q3 		$1.38M Buy
66,947
+5,681
+9% +$131K 0.01% 964
2024
Q2 		$1.37M Sell
61,266
-2,229
-4% -$53.1K 0.01% 961
2024
Q1 		$1.75M Buy
63,495
+2,301
+4% +$63.9K 0.01% 936
2023
Q4 		$1.87M Sell
61,194
-10,486
-15% -$301K 0.01% 872
2023
Q3 		$2.27M Sell
71,680
-14,962
-17% -$580K 0.02% 767
2023
Q2 		$3.53M Buy
86,642
+3,874
+5% +$157K 0.03% 648
2023
Q1 		$3.08M Sell
82,768
-3,867
-4% -$152K 0.03% 698
2022
Q4 		$3.02M Buy
86,635
+14,977
+21% +$712K 0.03% 708
2022
Q3 		$4.01M Sell
71,658
-7,981
-10% -$495K 0.04% 586
2022
Q2 		$4.12M Buy
79,639
+3,320
+4% +$169K 0.03% 625
2022
Q1 		$5.55M Buy
76,319
+4,877
+7% +$413K 0.03% 612
2021
Q4 		$8.45M Buy
71,442
+14,563
+26% +$1.82M 0.04% 494
2021
Q3 		$7.63M Buy
56,879
+26,388
+87% +$4M 0.05% 488
2021
Q2 		$4.94M Sell
30,491
-617
-2% -$48K 0.03% 686
2021
Q1 		$2.5M Buy
+31,108
New +$2.09M 0.02% 919

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Guggenheim Capital's NTLA Position: Q2 2026 in Review

Guggenheim Capital increased its Intellia Therapeutics (NTLA) stake by 8.4% in Q2 2026, buying an estimated $64.7K and bringing the position to 59,739 shares worth $1.01M. The position accounts for 0.01% of the portfolio, ranked #1018.

Guggenheim Capital first reported a position in NTLA in Q1 2021 and has held it in 22 quarters since. The position peaked at $8.45M in Q4 2021. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Guggenheim Capital held 59,739 shares of Intellia Therapeutics worth $1.01M as of Q2 2026.
  • Guggenheim Capital bought 4,622 Intellia Therapeutics shares in Q2 2026, an estimated $64.7K.
  • Intellia Therapeutics made up 0.01% of Guggenheim Capital's portfolio in Q2 2026, its #1018 holding.
  • Guggenheim Capital first reported a position in Intellia Therapeutics in Q1 2021 and has held it in 22 quarters since.
  • Guggenheim Capital's Intellia Therapeutics position peaked at $8.45M in Q4 2021.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Guggenheim Capital's 13F filing for Q2 2026, filed 12 Aug 2026.